Updated Testing Algorithms for Plasma Cell Proliferative Disorders: Xinjie Xu, Ph.D.
Xinjie Xu, Ph.D., a cytogeneticist and a molecular geneticist who specializes in genetic testing for hematological malignancies, explains Mayo Clinic Laboratories' updated approach to genetic testing for risk stratification of patients newly diagnosed wit
Episode 51 of the Answers from the Lab podcast, hosted by Mayo Clinic Laboratories, titled "Updated Testing Algorithms for Plasma Cell Proliferative Disorders: Xinjie Xu, Ph.D." was published on December 15, 2020 and runs 8 minutes.
December 15, 2020 ·8m · Answers from the Lab
Summary
Xinjie Xu, Ph.D., a cytogeneticist and a molecular geneticist who specializes in genetic testing for hematological malignancies, explains Mayo Clinic Laboratories' updated approach to genetic testing for risk stratification of patients newly diagnosed with plasma cell proliferative disorders, such as multiple myeloma. Based on recently published data, the new testing algorithms focus on use of fluorescence in situ hybridization (FISH) panels, rather than chromosome studies.
Episode Description
Tell us a little bit about your background and about yourself.
Give us a brief overview of what are the previous approaches that have been used in the past for multiple myeloma testing.
So can you take a moment and talk to me about the new approach and the new algorithm that your laboratory is working on implementing?
So how does this new approach really benefit both hospitals across the country that we serve and the patients that they're trying to treat?
What else is the lab working on when it comes to our multiple myeloma testing and our algorithms?
Resources
Plasma Cell Proliferative Disorder [A Test in Focus]
Plasma Cell Proliferative Disorder, FISH, Bone Marrow (Mayo test ID: PCPDS)
Chromosome Analysis, Hematologic Disorders, Bone Marrow (Mayo test ID: CHRBM)
Similar Episodes
Apr 5, 2026 ·6m
Apr 2, 2026 ·5m
Mar 29, 2026 ·7m
Mar 19, 2026 ·5m
Mar 15, 2026 ·7m
Mar 9, 2026 ·12m